Published in Int J Chron Obstruct Pulmon Dis on January 01, 2007
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res (2011) 1.89
Extrinsic Threshold PEEP Reduces Post-exercise Dyspnea in COPD Patients: A Placebo-controlled, Double-blind Cross-over Study. Cardiopulm Phys Ther J (2011) 0.87
Sequential comparison of tiotropium to high-dose ipratropium in patients with chronic obstructive pulmonary disease in a practice setting. Int J Chron Obstruct Pulmon Dis (2009) 0.76
Which bronchodilator in COPD? Int J Chron Obstruct Pulmon Dis (2007) 0.75
The Relationship between Airway Inflammation and Exacerbation in Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis (Seoul) (2017) 0.75
Standardisation of spirometry. Eur Respir J (2005) 48.20
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA (1994) 10.46
Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax (2004) 6.41
Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med (2007) 5.51
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19
Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med (2005) 4.95
Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA (2003) 4.88
Burden of disease--implications for future research. JAMA (2001) 4.75
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J (2002) 4.68
Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax (2003) 4.53
Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med (2002) 4.27
Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med (2002) 4.11
Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax (2003) 3.90
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J (2002) 3.66
Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med (1997) 3.31
The economic burden of COPD. Chest (2000) 3.21
Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J (2004) 3.19
Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Intern Med (2006) 3.16
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease--2003. Can Respir J (2003) 3.14
Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis (1986) 3.03
Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest (2006) 3.01
Minimal clinically important differences in COPD lung function. COPD (2005) 3.00
Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med (2003) 2.94
Interpreting COPD prevalence estimates: what is the true burden of disease? Chest (2003) 2.78
Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J (2005) 2.60
Pharmacoeconomic evaluation of COPD. Chest (2000) 2.35
Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest (2005) 2.15
Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 2.01
Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev (2005) 2.00
Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest (2003) 1.90
Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest (2003) 1.85
Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest (2005) 1.83
Tiotropium for stable chronic obstructive pulmonary disease: A meta-analysis. Thorax (2006) 1.76
Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1996) 1.69
The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J (2006) 1.65
The pharmacological properties of tiotropium. Chest (2000) 1.53
Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 1.51
The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest (2000) 1.43
Pooled clinical trial analysis of tiotropium safety. Chest (2006) 1.35
Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc (2005) 1.31
Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax (2003) 1.31
The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther (2004) 1.31
The effect of tiotropium on hyperinflation and exercise capacity in chronic obstructive pulmonary disease. Respiration (2005) 1.27
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J (2004) 1.26
Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J (2004) 1.25
The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med (2004) 1.19
Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther (2005) 1.19
Spirometry and dyspnea in patients with COPD. When small differences mean little. Chest (1996) 1.18
One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther (2004) 1.17
Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J (2002) 1.09
Tiotropium for the treatment of stable chronic obstructive pulmonary disease: a systematic review with meta-analysis. Pulm Pharmacol Ther (2006) 1.06
Impact of chronic obstructive pulmonary disease on quality of life: the role of dyspnea. Am J Med (2006) 1.05
Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease. Pharmacotherapy (2005) 1.05
[Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities]. Pneumologie (2006) 1.05
Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J Aerosol Med (2001) 1.03
Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol (2003) 1.02
Effect of atropine on sputum production. Thorax (1975) 0.96
An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. Chest (2006) 0.96
Acetylcholine stimulates bronchial epithelial cells to release neutrophil and monocyte chemotactic activity. Am J Physiol (1992) 0.95
Dynamic hyperinflation: is it worth measuring? Proc Am Thorac Soc (2006) 0.93
Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Am J Respir Crit Care Med (2000) 0.93
The presence and functions of muscarinic receptors in human T cells: the involvement in IL-2 and IL-2 receptor system. Life Sci (2003) 0.92
Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis. Thorax (1994) 0.85
Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics (2004) 0.82
Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment. J Clin Pharmacol (2004) 0.81
Acute angle-closure glaucoma precipitated by local tiotropium absorption. Pulm Pharmacol Ther (2006) 0.79
The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding. Am J Med (2006) 0.78
Therapeutic gains of prolonged bronchial dilatation in chronic obstructive pulmonary disease. Ann Intern Med (2005) 0.77
[Postoperative intestinal paralysis caused by the muscarinic receptor blocker tiotropium bromide]. Urologe A (2005) 0.76
Azithromycin for prevention of exacerbations of COPD. N Engl J Med (2011) 8.66
A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med (2012) 4.10
Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med (2014) 3.51
Vitamin D levels and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study. Am J Respir Crit Care Med (2011) 2.64
Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med (2010) 2.60
Screening for lung cancer: the guidelines. Chest (2003) 1.29
Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med (2011) 1.05
Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study. Ther Adv Respir Dis (2008) 0.98
Viral pathogens in acute exacerbations of chronic obstructive pulmonary disease. Intern Emerg Med (2008) 0.95
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PLoS One (2013) 0.86
Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review. COPD (2005) 0.86
Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis (2012) 0.86
TORCH and UPLIFT: what has been learned from the COPD "mega-trials"? COPD (2009) 0.85
Effect of sleep skills education on sleep quality in patients attending a psychiatry partial hospitalization program. Prim Care Companion CNS Disord (2013) 0.85
Supplemental vitamin D and physical performance in COPD: a pilot randomized trial. Int J Chron Obstruct Pulmon Dis (2013) 0.84
Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization. COPD (2011) 0.83
Influence of lightweight ambulatory oxygen on oxygen use and activity patterns of COPD patients receiving long-term oxygen therapy. COPD (2012) 0.81
Management of acute exacerbations of chronic obstructive pulmonary disease in the elderly : an appraisal of published evidence. Drugs Aging (2007) 0.80
Responses to tiotropium in African-American and Caucasian patients with chronic obstructive pulmonary disease. Transl Res (2008) 0.80
Antibiotic prophylaxis for chronic obstructive pulmonary disease: resurrecting an old idea. Am J Respir Crit Care Med (2008) 0.79
Contemporary issues in the diagnosis and treatment of obstructive sleep apnea. Postgrad Med (2008) 0.78
Severe vitamin D deficiency: a biomarker of exacerbation risk? : a reply to Heulens. Am J Respir Crit Care Med (2013) 0.76
Inhaled corticosteroids for chronic obstructive pulmonary disease: a status report. Am J Respir Crit Care Med (2007) 0.75
Exhaled nitric oxide and steroid responses in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 0.75
Prevention of postextubation laryngeal oedema. Lancet (2007) 0.75
Sleep Disturbance Among HIV Infected and Uninfected Veterans. J Acquir Immune Defic Syndr (2016) 0.75
Implantable cardioverter-defibrillators in patients with COPD. Chest (2013) 0.75
Disease management as an evolving role for respiratory therapists. Respir Care (2006) 0.75
Managing stable COPD in 2009: incorporating results from recent clinical studies into a goal-directed approach for clinicians. Postgrad Med (2009) 0.75
A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium. Respir Med (2013) 0.75